H. Lundbeck A/S Release: Largest Prospective Study Evaluating The Effect Of Vigabatrin On Vision

PHILADELPHIA--(BUSINESS WIRE)--The largest prospective study evaluating vision changes in adult patients with refractory complex partial seizures (rCPS) will be available to view next month at the annual meeting of the American Epilepsy Society (AES) in Philadelphia. The single-arm, open-label study enrolled vigabatrin-naïve adult patients to evaluate changes in visual field and retinal structure during one-year exposure to vigabatrin, in addition to other anti-epileptic drugs (AEDs).

“As an unwavering ally to people living with challenging seizures, the Epilepsy Foundation is pleased with this ongoing research”

“It is crucial that we continue to study the risk of vision loss," said study investigator Kenneth D. Laxer, MD, professor emeritus of clinical neurology and neurosurgery, University of California San Francisco, and the medical director for the California Pacific Epilepsy Program. “We are looking forward to sharing the largest prospective study evaluating the effect of vigabatrin on vision in adult patients with rCPS.”

The presentation will be displayed at AES on Sunday, Dec. 6, from 8-11 a.m. in the Lundbeck Scientific Exhibit, Room 201B.

“As an unwavering ally to people living with challenging seizures, the Epilepsy Foundation is pleased with this ongoing research,” said Phil Gattone, president and CEO of the Epilepsy Foundation. “Each new piece of data helps improve our understanding of vigabatrin.”

About Lundbeck

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer’s disease, bipolar disorder, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind. Read more at www.lundbeck.com/global/about-us/progress-in-mind.

In 2015, Lundbeck can celebrate its 100th anniversary. During the past century, millions of people have been treated with our therapies. It is complex and challenging to develop improved treatments for brain disease, but we keep our focus: There is still so much we need to achieve in the next 100 years to ensure a better life for people living with brain disease.

Lundbeck has approximately 5,500 employees in 57 countries who are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries.

Lundbeck in the U.S.

In the U.S., Lundbeck employs more than 900 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in hundreds of initiatives each year that support our patient communities.

To learn more, visit us at www.LundbeckUS.com and connect with us on Twitter at @LundbeckUS.



Matt Flesch
(847) 922-2871

Back to news